Could I answer that one?
I think she was referring to a group trial of 130 in Europe. It's bigger than that; there are two trials there. It's actually double that. I think the figures may have been mixed up somewhere. It's not just 130. There are two studies done in Europe with slightly different concentrations of the adjuvant and the antigen, essentially, so the numbers are not quite correct.
On the safety side, as I did explain originally, there is a whole safety database. For adjuvanted vaccines, it's H5N1, and then you switch over to the H1N1 virus for the actual efficacy part.
I think Paul wants to add to that.